Ovarian clear cell adenocarcinoma has a relatively poor prognosis among the ovarian cancer subtypes because of its high chemoresistance. Differential diagnosis of clear cell adenocarcinoma from other ovarian surface epithelial tumors is important for its treatment. Napsin A is a known diagnostic marker for lung adenocarcinoma, and expression of napsin A is reported in a certain portion of thyroid and renal carcinomas. However, napsin A expression in ovarian surface epithelial tumors has not previously been examined. In this study, immunohistochemical analysis revealed that in 71 of 86 ovarian clear cell adenocarcinoma patients (83%) and all of the 13 patients with ovarian clear cell adenofibroma, positive napsin A staining was evident. No expression was observed in 30 serous adenocarcinomas, 11 serous adenomas or borderline tumors, 19 endometrioid adenocarcinomas, 22 mucinous adenomas or borderline tumors, 10 mucinous adenocarcinomas, or 3 yolk sac tumors of the ovary. Furthermore, expression of napsin A was not observed in the normal surface epithelium of the ovary, epithelia of the fallopian tubes, squamous epithelium, endocervical epithelium, or the endometrium of the uterus. Therefore, we propose that napsin A is another sensitive and specific marker for distinguishing ovarian clear cell tumors (especially adenocarcinomas) from other ovarian tumors.
Napsin A is an aspartic proteinase that is abundantly expressed in normal lung and kidney tissue and is also frequently expressed in lung adenocarcinomas. [1] [2] [3] [4] Napsin A has a role in processing pulmonary surfactant B protein produced by alveolar type II pneumocytes; 5, 6 thus, it has been reported to be a good diagnostic marker for the confirmation of primary lung adenocarcinoma together with thyroid transcription factor 1 (TTF-1). [7] [8] [9] [10] [11] [12] [13] Expression of napsin A is also observed in the fetal kidney 14 and proximal tubules of the adult kidney, where it is most likely involved in protein catabolism. 15 In neoplasms other than lung cancer, napsin A expression is most frequently observed in papillary renal carcinoma (79%), followed by other subtypes of renal cell carcinoma and thyroid carcinoma. 16, 17 No expression was observed in breast, pancreatic, or colon carcinomas or mesotheliomas. 16 It remains unclear whether napsin A exhibits some relationship with ovarian cancer.
Ovarian clear cell adenocarcinoma is often associated with endometriosis, 18, 19 and we have recently shown that stress caused by excess iron leads to amplification of the Met gene and carcinogenesis in the ovary. 20, 21 Compared with serous adenocarcinoma, clear cell adenocarcinoma is resistant to standard platinum-based chemotherapy; 22 thus, survival rates in patients with advanced stages of ovarian clear cell adenocarcinoma are poor. Therefore, it is important to distinguish clear cell adenocarcinoma from other histological subtypes in ovarian cancer.
In this study, we analyzed a total of 195 cases of ovarian tumors and revealed that napsin A expression is frequently and specifically observed in clear cell tumors, clear cell adenocarcinomas, and adenofibromas.
Materials and methods

Patients and Tissue Samples
The local ethics committee (Internal Review Board) approved this study. Formalin-fixed paraffinembedded tumor samples from primary clear cell adenocarcinoma of the ovary were obtained from 73 patients who underwent surgical treatment from 1986 to 2009 at the Nagoya University Hospital and from 13 patients at the Nagoya City University Hospital during 2004-2013. Primary ovarian samples from 96 non-clear cell adenocarcinoma patients with ovarian tumors, 14 with atypical epithelium in endometriotic cysts, and 5 endometrial samples containing Arias-Stella reaction were obtained from 2004 to 2013 at the Nagoya City University Hospital, with the exception of 7 patients with serous adenocarcinoma and 6 patients with endometrioid adenocarcinoma, which were obtained from Nagoya University Hospital and Nagoya First Red Cross Hospital. All patients were treated with optimal debulking surgery. Histological diagnoses were reviewed and confirmed for all primary ovarian tumor samples by two experts in gynecological pathology (YY and TN).
Immunohistochemistry
Formalin-fixed paraffin-embedded ovarian tumor blocks were sectioned into 3-5 mm slices for immunohistochemistry. Sections from whole blocks were subjected to immunohistochemical analyses to evaluate focal positivity. An anti-napsin A clone IP64 (Leica Biosystems, Wetzlar, Germany) primary antibody was used for immunohistochemical staining. Antibody binding was visualized using the auto-immunostaining apparatus Leica BOND MAX system (Leica Biosystems) according to the manufacturer's instructions, which included a heated incubation of the slides for 20 min in antigen retrieval buffer with an approximate pH of 9. Immunostaining of negative controls without primary antibody was also carried out in cases with excessive hemosiderosis. Napsin A staining was scored as weak (1 þ ) or intense (2 þ ), and we attempted to score the immunostaining negative/ o10 (10), 10-20 (20) 
Results
Napsin A expression was rather exclusively seen in the clear cell tumors including 86 ovarian clear cell adenocarcinoma cases (11 of which were accompanied by a clear cell adenofibromatous component) and two independent clear cell adenofibroma cases. Of 86 ovarian clear cell adenocarcinoma cases, 71 cases (83%) were napsin A-positive and 15 cases (17%) were napsin A-negative. A total of 58 of the 71 positive cases showed 2 þ staining, and the remaining 13 cases were scored 1 þ . More than half of the positive cases showed 2 þ immunostaining of more than 60% of the tumor cells (Table 1) . Totally, the range of positivity for each case and the mean or median of the distribution were 20-100 (mean 61, median 70) %, and 30-90 (mean 62, median 70) % in the 1 þ cases. All the remaining cases other than clear cell adenocarcinoma (30 serous adenocarcinoma, 19 endometrioid adenocarcinoma, 10 mucinous adenocarcinoma, 11 serous adenoma and borderline tumors, and 22 mucinous adenoma or borderline tumors, and 3 yolk sac tumors) were negative. The results of the histological features and immunostaining are summarized in Table 1 . Figure 1 shows several representative images of the histology and napsin A immunostaining. Intense staining in the cytoplasm was observed in clear cell adenocarcinoma tumor cells (Figures 1a and b) but not in a typical serous adenocarcinoma (Figures 1c and d) . Positive (16, 20) staining was also observed in the cytoplasm of clear cell adenofibroma (Figures 1e and f) . However, five cases (three serous adenocarcinoma and two endometrioid adenocarcinoma) contained clear cell-or hob-nail-like change resembling clear cell adenocarcinoma (Figure 2a) , and focal immunostaining of napsin A was observed in two of the five cases ( Figure 2b ). As the area of the positive staining did not exceed 10% of the tumor on the section, we considered these cases as napsin A-negative. Furthermore, we analyzed napsin A expression using 14 cases of endometriotic cysts containing atypical epithelium. Of the 14 cases, 11 were accompanied with ovarian adenocarcinoma, 3 of which were endometrioid and the other 8 clear cell adenocarcinomas. Interestingly, atypical epithelium of five cases, all of which contained clear cell adenocarcinoma component, was positive at least focally by napsin A immunostaining (Table 1 and Figures 2c and d) . All of the five endometrial samples with Arias-Stella reaction were also positive for napsin A, although the percentage of positive glands in each case varied (Table 1 and Figures 2e and f) . Other normal tissue samples (three endometrial, two endocervical epithelia, one squamous epithelium of the uterine cervix, one ovarian surface epithelium, and one epithelium of adenomyosis) were all negative for napsin A.
Discussion
Clear cell adenocarcinoma of the ovary has recently been regarded as a unique subtype of ovarian cancer with specific cytokine production and frequent amplification of the Met gene, which is associated with endometriosis (reviewed by Penson et al 23 ).
Furthermore, ovarian clear cell adenocarcinoma generally is chemoresistant, 24 likely because of its relatively slow growth rate. These characteristics highlight the importance of distinguishing clear cell adenocarcinoma from other ovarian carcinomas. Clear cell adenocarcinoma may exhibit papillary histology similar to that of serous adenocarcinomas, 25, 26 and serous borderline tumors may have hob-nail-like cells mimicking clear cell adenocarcinoma pathology. 27 Endometrioid neoplasms may also contain clear cells; 28 thus, a differential diagnosis between clear cell adenocarcinoma and other histological subtypes is necessary. Some yolk sac tumors also show similar histology to clear cell adenocarcinoma. 29 As a fraction of ovarian clear cell adenocarcinoma may produce alphafetoprotein, 30, 31 diagnostic markers distinguishing between these two tumors are also required. Recently, several molecules have been proposed as specific markers for clear cell adenocarcinoma of the ovary. Among them, hepatocyte nuclear factor 1 beta (HNF1b) seems to be the best because of its high sensitivity and specificity. 32, 33 However, one study reported HNF1b positivity in the nuclei of normal and tumor cells in the endometrium, 34 and the establishment of other markers may also be useful for differential diagnosis of clear cell adenocarcinoma. Annexin-A4, 35, 36 HOXA10, 37 phospho-serine aminotransferase, 36 and glypican 3 38 are all suitable candidates. A recent study has shown that a certain proportion of papillary serous adenocarcinoma also exhibits Annexin-A4 expression related to chemoresistance, 39 and the expression of HOXA10 or glypican 3 is less frequently associated with poor outcome. 37, 38, 40 Glypican 3 is also known to be expressed in yolk sac tumors of the ovary. 38 In this study, all of the 93 primary ovarian surface epithelial tumors that were not of the clear cell subtype and three cases of yolk sac tumors were all negative for napsin A staining, with the exception of focal (o10% area) staining of serous and endometrioid adenocarcinoma cases with clear cell-or hob-nail changes resembling clear cell adenocarcinoma. Thus, we consider napsin A to be another suitable marker to specifically distinguish clear cell adenocarcinoma from other ovarian tumors with a relatively high sensitivity. Furthermore, because napsin A is an established marker for lung adenocarcinomas, [7] [8] [9] [10] [11] [12] [13] we assume that napsin A immunostaining will be easily applied to routine surgical pathology specimens in laboratories. In this study, we determined the criteria for positive napsin A immunostaining as 410% tumor area for differential diagnosis between histological subtypes of ovarian adenocarcinomas, and given that focal positivity is observed in those other than clear cell adenocarcinoma, careful interpretation is required when applying this method on small biopsy specimen. In this study, napsin A was expressed in all of the 13 clear cell adenofibroma samples. However, no expression was observed in the normal endometrium and adenomyosis samples. All of the six endometriosis cases not accompanied with clear cell adenocarcinoma including those with endometrioid adenocarcinomas were also negative. However, five of the eight cases with both endometriosis and clear cell adenocarcinoma, the atypical and normallooking epithelium at the surface of the endometriotic cysts showed at least focal napsin A positivity. As positive expression of HNF1b is reported in the nuclei of the epithelial cells in the majority of the cases with endometriosis, 33 it is possible that napsin A may have a different role than HNF1 b in ovarian clear cell adenocarcinoma tumor cells. However, further analysis using more cases is necessary for clarification. Most recently, similar studies also have demonstrated frequent napsin A expression in clear cell adenocarcinomas of the ovary and endometrium. 41, 42 In this study, endometrial epithelial cells undergoing Arias-Stella reaction were also frequently positive for napsin A, and more studies are required for the evaluation of the biological meanings of these findings. Loss of napsin A expression is associated with a poor prognosis in lung cancer patients, 43 and some of our cases had also lost napsin A expression in tumor cells with high-grade morphology or Met amplification (data not shown). In this study, Recent studies have shown that napsin A is expressed in various tumors other than lung adenocarcinomas, including pulmonary sclerosing hemangioma, renal and thyroid carcinomas, and adrenal cortical neoplasms. 16, 17, [44] [45] [46] Renal papillary carcinomas are known to exhibit Met amplification, and renal clear cell carcinomas are known to exhibit vHL mutations leading to overexpression. 47 Thus, we consider that clear cell adenocarcinomas of the ovary and kidney have many common characteristics, including clear cell or papillary morphology, and gene mutation and expression. 48 Lung metastases of renal cancers are difficult to distinguish from primary lung adenocarcinomas by napsin A immunostaining, 49 and our data highlight this difficulty by revealing possible napsin A expression in lung metastases of clear cell adenocarcinoma of the ovary.
In conclusion, we have demonstrated that napsin A is expressed in the majority of ovarian clear cell adenocarcinoma and all of the clear cell adenofibromas. We suggest that napsin A should be included in the immunohistochemical panel for the differential diagnosis of ovarian surface epithelial tumors.
